慢性粒单核细胞白血病:2024年诊断、风险分层和管理更新
该综述更新了慢性粒单核细胞白血病(CMML)的诊断标准、风险分层与治疗。诊断需持续单核细胞增多、骨髓形态符合、原始细胞<20%及克隆性证据;Mayo分子模型分层对应中位生存16至97个月;异基因移植是唯一可治愈手段,药物以羟基脲和去甲基化药物为主。
要点
- 诊断要求持续>3个月外周血单核细胞≥0.5×10^9/L且占白细胞≥10%,骨髓或外周血原始细胞<20%。
- Mayo分子模型高危、中危2、中危1、低危对应中位生存16、31、59、97个月。
- 异基因移植是唯一可治愈手段,适用于Mayo分子模型高危/中危2患者。
核心结论
- CMML是兼具骨髓增生异常综合征和骨髓增殖性肿瘤特征的克隆性造血干细胞疾病,有向白血病转化的固有风险(约15%-20%/3-5年)。
- 异基因造血干细胞移植是唯一能确保治愈或长期生存的治疗方式,适用于Mayo分子模型高危/中危2患者。
- 药物治疗目前不能改变疾病进程,包括羟基脲和去甲基化药物。
研究设计与样本
- 综述,汇总CMML的诊断标准、风险分层模型与治疗进展。
- 引用一项3期研究(DACOTA)比较高危MP-CMML中羟基脲与地西他滨的疗效。
主要发现
- 细胞遗传学异常见于约30%患者,>95%携带体细胞突变:TET2约60%、SRSF2约50%、ASXL1约40%、RAS通路约30%等。
- ASXL1和DNMT3A突变及TET2无突变对总生存有负面影响,ASXL1野生型/TET2突变型基因型有利。
- Mayo分子模型风险因素包括截短型ASXL1突变、绝对单核细胞计数>10×10^9/L、血红蛋白<10 g/dL、血小板计数<100×10^9/L及循环未成熟髓系细胞。
- DACOTA研究显示高危MP-CMML中羟基脲与地西他滨总生存相似(23.1个月 vs 18.4个月),但地西他滨缓解率更高(56% vs 31%)。
关键数值与推荐
- 诊断标准:持续>3个月外周血单核细胞增多(≥0.5×10^9/L;单核细胞≥10%白细胞计数),骨髓形态符合,骨髓或外周血原始细胞<20%(包括前单核细胞),且有细胞遗传学或分子克隆性证据。
- Mayo分子模型分层:高危(≥3个风险因素)、中危2(2个风险因素)、中危1(1个风险因素)、低危(无风险因素),对应中位生存16、31、59、97个月。
- 根据白细胞计数≥13×10^9/L与否分为骨髓增殖型(MP-CMML)或骨髓增生异常型(MD-CMML)。
临床怎么用
- Mayo分子模型高危/中危2患者应尽早考虑异基因造血干细胞移植。
- 溶菌酶诱导的肾病需在白细胞增多期间密切监测肾功能,是细胞减灭治疗的潜在指征。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms, characterized by prominent monocytosis and an inherent risk for leukemic transformation (~15%-20% over 3-5 years). DIAGNOSIS: Newly revised diagnostic criteria include sustained (>3 months) peripheral blood (PB) monocytosis (≥0.5 × 109/L; monocytes ≥10% of leukocyte count), consistent bone marrow (BM) morphology, <20% BM or PB blasts (including promonocytes), and cytogenetic or molecular evidence of clonality. Cytogenetic abnormalities occur in ~30% of patients, while >95% harbor somatic mutations: TET2 (~60%), SRSF2 (~50%), ASXL1 (~40%), RAS pathway (~30%), and others. The presence of ASXL1 and DNMT3A mutations and absence of TET2 mutations negatively impact overall survival (ASXL1WT/TET2MT genotype being favorable). RISK STRATIFICATION: Several risk models serve similar purposes in identifying high-risk patients that are considered for allogeneic stem cell transplant (ASCT) earlier than later. Risk factors in the Mayo Molecular Model (MMM) include presence of truncating ASXL1 mutations, absolute monocyte count >10 × 109/L, hemoglobin <10 g/dL, platelet count <100 × 109/L, and the presence of circulating immature myeloid cells; the resulting 4-tiered risk categorization includes high (≥3 risk factors), intermediate-2 (2 risk factors), intermediate-1 (1 risk factor), and low (no risk factors); the corresponding median survivals were 16, 31, 59, and 97 months. CMML is also classified as being "myeloproliferative (MP-CMML)" or "myelodysplastic (MD-CMML)," based on the presence or absence of leukocyte count of ≥13 × 109/L. TREATMENT: ASCT is the only treatment modality that secures cure or long-term survival and is appropriate for MMM high/intermediate-2 risk disease. Drug therapy is currently not disease-modifying and includes hydroxyurea and hypomethylating agents; a recent phase-3 study (DACOTA) comparing hydroxyurea and decitabine, in high-risk MP-CMML, showed similar overall survival at 23.1 versus 18.4 months, respectively, despite response rates being higher for decitabine (56% vs. 31%). UNIQUE DISEASE ASSOCIATIONS: These include systemic inflammatory autoimmune diseases, leukemia cutis and lysozyme-induced nephropathy; the latter requires close monitoring of renal function during leukocytosis and is a potential indication for cytoreductive therapy.
引用
- Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. Am J Hematol. 2024. PMID: 38450850. doi:10.1002/ajh.27271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。